Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Monte Rosa Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$24.07M, down 186.8% year over year. For fiscal 2025 it was -$22.80M, down 154.3% from the year before. The highest annual figure on record is $42.00M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.80M | -154.3% |
| FY2024 | Dec 31, 2024 | $42.00M | – |
| FY2023 | Dec 31, 2023 | -$43.80M | – |
| FY2022 | Dec 31, 2022 | -$92.47M | – |
| FY2021 | Dec 31, 2021 | -$59.36M | – |
| FY2020 | Dec 31, 2020 | -$23.05M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$37.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.01M | -133.4% |
| Q3 FY2025 | Sep 30, 2025 | $100.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$34.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$45.49M | – |
| Q4 FY2024 | Dec 31, 2024 | $128.92M | +335.0% |
| Q3 FY2024 | Sep 30, 2024 | -$20.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.17M | – |
| Q4 FY2023 | Dec 31, 2023 | $29.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.96M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.79M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.82M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.57M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.89M | – |
See a number that looks wrong?